ArticleTuberculosis and respiratory diseases2025
Change in Exacerbation Rate of Asthma Patients before and after COVID-19 Infection.
Article in Tuberculosis and respiratory diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Asthma control and exacerbation risk following SARS-CoV-2 infection in the post-acute COVID-19 phase: a systematic review.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2026Article
- Engagement in Particulate Matter Exposure Reduction Behaviors Across Diverse Clinical Cohorts.Medicina (Kaunas, Lithuania) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundCoronavirus disease 2019 (COVID-19) significantly impacted healthcare utilization and disease outcomes worldwide. During the pandemic, overall asthma exacerbations reportedly declined; however, the specific effect of COVID-19 infection on subsequent exacerbation patterns in asthma patients remains unclear.
methodsUsing a nationwide health insurance claims database from South Korea, we identified patients who had both asthma and a confirmed COVID-19 diagnosis in 2020. We defined the pre-COVID-19 period as the 12 months immediately preceding the date of each patient's COVID-19 diagnosis, and the post-COVID-19 period as the 12 months following that date. Baseline characteristics, annual exacerbation rates, and direct medical costs were compared between these two timeframes.
resultsAmong 82,825 confirmed COVID-19 cases, 2,965 patients with asthma met the inclusion criteria. Compared to the pre-COVID-19 period, the proportion of patients experiencing moderate and moderate-to-severe exacerbations decreased, whereas after COVID-19 infection, severe exacerbations increased. A binomial mixed model showed that moderate and moderate-to-severe exacerbations declined significantly (incidence rate ratio [IRR]=0.848, p<0.001; and IRR=0.912, p<0.001, respectively), while after COVID-19 infection, severe exacerbations increased (IRR=1.220, p<0.001). Of those who were non-exacerbators prior to COVID-19, 10.8% became exacerbators. This group was older, more frequently male, and had a greater comorbidity burden. Total direct medical costs escalated markedly from USD (2,965.50 to 4,850.41; p<0.001), particularly among those who developed as exacerbators after COVID-19 infection.
conclusionCOVID-19 infection had a paradoxical impact on asthma exacerbations, reducing moderate exacerbations, while increasing severe events. The substantial rise in medical costs contributes to the economic burden of asthma care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.